SEC Tracker
Get the app

Possible new VRTX shares

VRTXDilution

Known so far: no new shares from the prospectus covers read · shelf not limited by the baby-shelf rule · not yet read: warrants, converts, ATM.

Shelf room

  • Room today not capped by the baby-shelf rule ($113B float, Jun 30, 2025)
How this is worked out

Shelf room on the S-3ASR of Feb 13, 2025: not limited by the baby-shelf rule, because the $113B public float stated as of Jun 30, 2025 is $75M or more. Sources: S-3ASR Feb 13, 2025, effective Feb 13, 2025 · public float, as of Jun 30, 2025.

What could become new Vertex Pharmaceuticals (VRTX) shares: options and RSUs, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

VRTX dilution ladder

Every source of new shares on record, from the filings that created it.

253.5M outstanding

  1. Outstandingas of Oct 31, 2026 (10-Q filed Nov 3) · share count on the cover page
    253.5M
  2. Options and RSUs0 options, 0 RSUs10-Q Nov 3, 2026 · securities left out of diluted EPS
    +0

Not stated in the filings we read: an ATM program, warrants, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Shares outstanding

254M

Feb 2025 to Oct 2026: from 257M to 254M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.